Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach

• Autores principales: Elena M. Tosca (Autor), Glenn Gauderat (Autor), Sylvain Fouliard (Autor), Mike Burbridge (Autor), Marylore Chenel (Autor), Paolo Magni (Autor)
• Formato: Libro
• Publicado: Wiley, 2021-11-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract MET receptor tyrosine kinase inhibitors (TKIs) can restore sensitivity to gefitinib, a TKI targeting epidermal growth factor receptor (EGFR), and promote apoptosis in non‐small cell lung cancer (NSCLC) models resistant to gefitinib treatment in vitro and in vivo. Several novel MET inhibitor...